Europe Gene Therapy Market - Industry Trends and Forecast to 2030

Europe Gene Therapy Market - Industry Trends and Forecast to 2030

Europe Gene Therapy Market, By Vector Type (Viral Vector and Non-Viral Vector), Method (Ex-Vivo and In-Vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Disease, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research Institutes, and Others), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe) Industry Trends and Forecast to 2030.

Market Definition

Gene therapy is a medical strategy that addresses the underlying genetic issue to treat or prevent disease. Instead of drugs or surgery, gene therapy procedures allow doctors to treat a problem by changing a person's genetic composition. A select few disorders, including an eye condition called Leber congenital amaurosis and a muscle condition called spinal muscular atrophy, are being treated with gene therapy. To ensure that they will be secure and efficient, many other gene therapies are undergoing study. Medical professionals aim to apply the promising genome editing technique soon to cure human illnesses.

The ability to successfully transport a therapeutic gene to a target cell is the essential prerequisite for gene therapy to be successful. Once transported, that gene must go to the cell wall's nucleus, a model for making protein molecules. The protein then produces the principal therapeutic action. For instance, cell destruction might be used to treat tumors, whereas cell preservation might be used in the case of neurodegenerative illness. However, strict regulations and standards for the approval and commercialization of products are expected to restrain market growth.

Market Segmentation

The Europe gene therapy market is segmented into four notable segments: vector type, method, application, and end user.
• On the basis of vector type, the market is segmented into viral vector and non-viral vector
• On the basis of method, the market is segmented into ex-vivo and in-vivo
• On the basis of application, the market is segmented into oncological disorders, cardiovascular diseases, infectious diseases, rare diseases, neurological disorders, and other diseases
• On the basis of end user, the market is segmented into cancer institutes, hospitals, research institutes, and others

Market Players

Some major companies dealing in the Europe gene therapy market are:
• Biogen
• Kite Pharma
• Novartis AG
• Bristol-Myers Squibb Company
• Oxford Biomedica
• Amgen, Inc.
• Ferring B.V.
• Dendreon Pharmaceuticals LLC.
• Janssen Europe Services, LLC,
• uniQure NV.
• Spark Therapeutics, Inc.
• AGC Biologics.
• Orchard Therapeutics plc
• Mallinckrodt Pharmaceuticals
• Bluebird Bio Inc.
• Sibiono GeneTech Co. Ltd.
• AnGes, Inc.
• CHIESI Farmaceutici S.p.A.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.